Innovators and generics, neither are wholly satisfied with the current Canadian system of intellectual property and related rights (IPRs). Ongoing trade negotiations between Canada and the European Union has fuelled the debate over effective IPR for innovative pharmaceutical products.
Click here to read the full article, written by Steven B. Garland and Daphne C. Lainson of our Ottawa office, which appeared in the August 2012 issue of Intellectual Property Magazine.
Related Publications & Articles
-
Twice is not nice – second notice of allegation may be abusive
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines (Notice of Compliance) Reg...Read More -
FCA upholds inducement of infringement findings relating to paliperidone palmitate
On January 12, 2024, the Federal Court of Appeal (FCA) dismissed both appeals: Apotex Inc v Janssen Inc, 2024 FCA 9 and Pharmascience Inc v Janssen Inc, 2024 FCA 10.Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More